ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
lncRNA H19 as a molecular rheostat in autoimmunity: orchestrating miRNA-mediated gene regulation and immune cell reprogramming.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Estradiol Reverses Ovariectomy-Induced Small RNA-mRNA Stress Signatures to Restore Neuroendocrine, Synaptic, and Immune Homeostasis in the Hypothalamus.Biomolecules · 2026Article
- Exosomes-Transferred lncRNA H19 Reverses Osimertinib Resistance by Upregulating PTEN via Sponging miR-148-3p in Non-Small Cell Lung Cancer.Oncology research · 2026Article
- Salivary Biomarkers for the Diagnosis of Sjögren's Syndrome: A Review of the Last Decade.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long non-coding RNA H19 (lncRNA H19) functions as a crucial regulator that controls various biological processes especially in immunological responses and autoimmune disease pathogenesis. Autoimmunity develops through complex interactions between genetic factors and environmental triggers and epigenetic changes which result in improper immune reactions against self-antigens. Research findings demonstrate that lncRNA H19 functions as a key regulator which controls immune cell behavior and controls inflammatory pathways and epigenetic regulatory mechanisms. The immune system dysregulation caused by H19 leads to changes in autoimmune disease progression and clinical symptom development. The balance between pro-inflammatory and anti-inflammatory cytokine production is controlled by lncRNA H19 through its interactions with NF-κB signaling cascade and multiple microRNA networks. The immunological tolerance mechanism depends on lncRNA H19 to control T cell differentiation through its regulation of regulatory T cells and T-helper 17-cell populations. The altered expression of lncRNA H19 in autoimmune diseases makes it an attractive subject for research as both a diagnostic biomarker and therapeutic target. This review summarizes recent findings to explain how lncRNA H19 functions in autoimmune disease immunopathogenesis and its therapeutic potential.
Indexed as
Identifiers
40445334What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.